Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial - Université de Lorraine Access content directly
Journal Articles European Journal of Heart Failure Year : 2021

Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial

Abstract

Aims: In heart failure with reduced ejection fraction (HFrEF), guidelines recommend up-titration of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptors blockers (ARBs) to the maximum tolerated dose. However, some studies suggest that women might need lower doses of ACEi/ARBs than men to achieve similar treatment benefit. Methods and results: The HEAAL trial compared low vs. high dose of losartan. We reassessed the efficacy and safety of high- vs. low-dose in men vs. women using Cox models and machine learning algorithms. The mean age was 66 years and 30% of patients were women. Men appeared to have benefited more from high-dose than from low-dose losartan, whereas women appeared to have responded similarly to low and high doses [hazard ratio (95% confidence interval) comparing high- vs. low-dose losartan for the composite outcome of all-cause death or all-cause hospitalization: 0.89 (0.81-0.98) in men and 1.10 (0.95-1.28) in women; interaction P = 0.018]. Female sex clustered along with older age, ischaemic heart failure, New York Heart Association class III/IV, and estimated glomerular filtration rate <60 mL/min. Patients with these features had a poorer response to high-dose losartan. Subgroup analyses supported no benefit from high-dose losartan in patients with poorer kidney function and severe heart failure symptoms. Conclusions: Compared with men, women might need lower doses of losartan to achieve similar treatment benefit. However, beyond sex, other factors (e.g. kidney function, age, and symptoms) may influence the response to high-dose losartan, suggesting that sex-based subgroup findings may be biased by other confounders.
Fichier principal
Vignette du fichier
EJHF_HEAAL_Dosing_Paper.pdf (439.85 Ko) Télécharger le fichier
EJHF_HEAAL_Dosing_Supplement.pdf (398.11 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03701735 , version 1 (22-06-2022)

Identifiers

Cite

João Pedro Ferreira, Marvin A Konstam, John J.V. Mcmurray, Javed Butler, Nicolas Girerd, et al.. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. European Journal of Heart Failure, 2021, 23 (9), pp.1477-1484. ⟨10.1002/ejhf.2255⟩. ⟨hal-03701735⟩
24 View
40 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More